Combating Gastroenteritis – Advanced Diagnostic Techniques for Effective Management
Combating Gastroenteritis – Advanced Diagnostic Techniques for Effective Management
Gastroenteritis, often referred to as stomach flu or a stomach bug, affects millions globally each year with symptoms such as diarrhoea, vomiting, abdominal pain, and fever. It is primarily caused by viral and bacterial infections, with rotavirus, norovirus, and Clostridium difficile being the main culprits.
At Randox, we’re dedicated to improving healthcare worldwide. That’s why we’ve produced an educational guide on gastroenteritis and the latest advancements in diagnostic techniques, including a range of novel gastroenteritis test for the Vivalytic POCT system. In this blog, we’ll look at a few of the key points raised in our latest educational guide. You can download this educational guide by clicking the below.
Why Gastroenteritis Matters
Gastroenteritis can lead to severe dehydration, especially in vulnerable groups like children and the elderly. It spreads mainly through the faecal-oral route, which includes consuming contaminated food and water. Prompt and accurate diagnosis is crucial for effective management.
Key Pathogens
Rotavirus
Rotavirus is a major cause of severe gastroenteritis in children. Highly contagious, it leads to rapid dehydration, making rehydration and supportive care essential. Vaccines like Rotarix and RotaTeq are effective in preventing infections.
Norovirus
Norovirus is responsible for most viral gastroenteritis outbreaks. Extremely contagious, it spreads quickly through direct contact and contaminated food. Symptoms include sudden vomiting and diarrhoea, often leading to dehydration. While there’s no specific treatment, staying hydrated is key.
Clostridium difficile
Clostridium difficile, or C. diff, is a leading cause of antibiotic-associated diarrhoea, particularly in healthcare settings. It produces toxins that cause inflammation and damage to the colon, requiring targeted antibiotic treatment for severe cases.
Advanced Diagnostics: The Vivalytic System
Accurate and timely detection of gastroenteritis pathogens is crucial for effective patient management. The Vivalytic Point of Care Testing (POCT) system, developed by Bosch Healthcare Solutions and Randox Laboratories, offers rapid and reliable diagnostics. This system helps healthcare professionals make quicker decisions, improving patient outcomes.
The Vivalytic Gastroenteritis Panels
The Vivalytic panels detailed in our guide include tests for rotavirus, norovirus, and Clostridium difficile. These panels utilise advanced molecular techniques to provide quick and accurate results, helping to streamline the diagnosis process and enhance patient care. By using these panels, healthcare providers can efficiently identify the specific pathogens responsible for gastroenteritis, allowing for targeted treatment and improved patient outcomes.
Features of the Vivalytic System
The Vivalytic system is user-friendly and efficient. It supports both High-Plex and Low-Plex testing, allowing for the simultaneous detection of multiple pathogens from a single sample. This versatility makes it an invaluable tool for healthcare professionals.
Conclusion
Gastroenteritis, caused by pathogens like rotavirus, norovirus, and Clostridium difficile, presents significant health challenges. Advanced diagnostic technologies, such as the Vivalytic system, are crucial in managing and controlling this condition. For a comprehensive understanding of gastroenteritis and innovative diagnostic techniques, download our detailed educational guide.
For more information on the Vivalytic, the panels mentioned, or any of our products, don’t hesitate to reach out to us at marketing@randox.com
Randox named as Company of the year
Randox tops the charts in Belfast Telegraph Top 100 Companies
Randox is the largest blood-sciences healthcare diagnostics company from the UK and Ireland. Established in 1982 by managing director Dr Peter FitzGerald, Randox manufactures more than four billion tests per year and has a global sales and distribution network supplying product to 145 countries. Randox estimates more than 400 million people, around 5% of the worldās population, receive a diagnosis involving Randox products each year. Key facilities are located at multiple sites within Northern Ireland, in Co Donegal, in West Virginia in the United States and in Bengaluru, India.
As a privately-owned company Randox invests heavily in research and development, committing up to 25% of turnover for the development of new diagnostic products. Recent testing developments include: Type 1 Diabetes Genetic Risk Score; an advanced PSA test to improve the predictive potential of PSA alone for prostate cancer; predictive bladder cancer testing panels; risk assessment for post operative acute kidney injury and chronic kidney disease; and wide-ranging quality control and external quality assurance capabilities to ensure the accuracy and reliability of laboratory results.
Randoxās innovative approach to R&D has allowed the development of allied capabilities outside the immediate world of human healthcare, including leading testing capabilities in the veterinary field, for toxicology and for the detection of harmful drug residues and pathogens in food.
Research and development programmes are not limited to the development of tests, but also includes the advanced analyser systems to process samples efficiently. This requires integral, advanced capabilities in electrical and mechanical engineering, optics, robotics and software engineering.
Over Ā£350m of investment has supported the development of a unique testing system to allow multiple tests to be run simultaneously on a single sample ā the Randox Biochip. This 9mm x 9mm platform, which allows up to 49 tests to be run simultaneously, greatly increases the diagnostic power available to clinicians to enable earlier, more accurate diagnosis and improved patient outcomes. Initially focused on proteomics, Randox has also greatly increased its genetic testing capabilities to increase predictive capabilities.
In order to support the model of diagnostically-led healthcare, Randox has developed the Randox Health brand, to provide public access to comprehensive testing. The aim is to empower the consumer and to enable a preventative approach to healthcare ā rather than rely upon the treatment of illness. Well over 20 clinics are now available across the UK and Ireland, including in partnership within John Lewis stores.
At the outset of the Covid-19 pandemic Randox was ideally placed to support the UKās requirement for a national Covid-19 testing programme. By mid-February 2020 Randox were amongst the global frontrunners in developing a Covid-19 test and had developed home sample collection and reporting capabilities. The company was engaged by Government from mid-March 2020 to support the UKās national testing programme ā at that time the complete NHS testing capability for Covid-19 was reported as 2,400 tests per day.
Rising to meet this unprecedented national demand markedly increased company turnover and profits. A post-pandemic assessment by consultants OCO Global concluded that Randoxās activities during the pandemic averted over 3,100 deaths, prevented 14,100 hospitalizations and enabled a Ā£8.3bn contribution to the UKās GDP.
Exiting from the pandemic and reverting to sector norms with a strong balance sheet, Randox is investing heavily in upgrading the companyās infrastructure and R&D programmes. Randox is also investing significant resources in expanding the business-to-consumer diagnostic offer under the Randox Health brand ā with clinics in the UK and Ireland, and US.
Noting the pressures upon all healthcare systems, and a need to transition from āillness managementā to more sustainable āpreventionā models, Randox is investing heavily for the future. Its aim is to ensure it is well positioned to support and enable healthcare transformation through improved diagnostics, to both increase system efficiencies and improve patient outcomes.
Joe Kennedy III, US special envoy for economic affairs visited Randox Science Park in Antrim last week to listen for presentations on Randox Laboratories MultiSTAT and RABTA analysers. He wrote in a foreword to the Belfast Telegraph article, āI congratulate everyone who has contributed to the success of Northern Irelandās Top 100 Companies. “From globally-recognised brands to indigenous firms, each company reflects the wide diversity of employers who generate prosperity and opportunity right across Northern Ireland.ā
Randox managing director Dr. Peter FitzGerald said it welcomed the accolade of being named number one company.
āThese results reflect the skills, commitment and agility of our people, and the capability of our unique technologies.
“As a team we were also able to call upon 40 years of diagnostic experience to meet the exceptional demands of Covid-19, while simultaneously supporting our established global customer base of healthcare laboratories. Crucial to this was our long term commitment to research and development which has always been a cornerstone of our business philosophy.
āRandox is committed to enhancing healthcare through more sensitive and accurate diagnostics to enable the prevention of disease and improve healthcare outcomes, whilst reducing the burden on healthcare services.
“Our profits will continue to be directed towards enabling our infrastructure and research and development, as well as accelerating better healthcare models and improving direct public access through our Randox Health clinics. Our ambition is to enable better health outcomes for all and we are committed to that goal.ā
Randox’s Sustainable Success with carbonfit
In the dynamic diagnostic testing sector, Randox is leading the charge towards sustainability with a clear vision and strategic partnership with carbonfit. Randox have a commitment to reducing carbon emissions and embracing renewable energy solutions which is setting a new standard for environmental responsibility within the industry.
- Aiming for complete elimination of emissions by 2050 whilst hitting milestones in the years leading up to this.
- Additionally, they are targeting a remarkable 95% reduction in Scope 3 emissions by 2050 whilst hitting milestones in the years leading up to this.
- Additionally, they are targeting a remarkable 95% reduction in Scope 3 emissions by 2050. These goals highlight Randox’s proactive approach to mitigating their environmental impact and aligning with global sustainability objectives.
Partnering with carbonfit, Randox has implemented a comprehensive carbon reduction plan that has yielded significant results. They have identified and implemented energy-saving measures that resulted substantial savings of c.600,000 kWh and a notable reduction of over 1,800 metric tonnes of C02 equivalent (TCO2e). These efforts have not only contributed to environmental sustainability but have also led to financial savings of approximately Ā£180,000 per year, demonstrating the synergies between sustainability and business efficiency.
Randox’s commitment to renewable energy is evident through their planned installation of solar PV systems in 2023 and 2024. By embracing clean energy technologies, Randox is further reducing their carbon footprint and contributing to a more sustainable energy landscape.
One of the main drivers for Randox to work with carbonfit was the need for a more efficient and advanced approach to managing carbon and energy. Transitioning away from manual spreadsheet-based methods, Randox leveraged carbonfit’s sophisticated platform for real-time data management, regulatory requirements including ESOS (Energy Savings Opportunity Scheme), PPN06/21 (Publicly Available Specification for the Assessment of the Life Cycle Greenhouse Gas Emissions of Goods and Services), and SECR (Streamlined Energy and Carbon Reporting), empowering Randox with streamlined operations and enhanced sustainability practices.
Randox’s partnership with carbonfit exemplifies their dedication to innovation, sustainability leadership, and responsible corporate practices. Together, they are driving meaningful change towards a greener future, where environmental stewardship and operational excellence go hand in hand.
PCR rapid tests for Candida auris for Vivalytic by Bosch now available
World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care.Ā
-
Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings.
-
Candida aurisĀ infection rates are on the rise in Germany and can cause severe infections, for example in the bloodstream (sepsis).
-
Hospitals can use the new screening test to detect colonization, allowing them to implement measures to contain outbreaks.
Bosch Healthcare solutions has developed a PCR test for detecting Candida auris (C. auris)Ā and on the Vivalytic platform. The test is a global innovation now available for order from distribution partners including Randox Laboratories Ltd. and R-Biopharm. This test enables the fully automated detection of the frequently multi-resistant fungus in less than an hour at the point of care. The rapid testing capability also makes it suitable for carrying out screenings when necessary. In contrast, traditional culture tests in centralized laboratories require one to three days, delaying diagnosis and the initiation of targeted treatment. āConsidering the heightened risk of severe progression in individuals with pre-existing conditions, we have developed a new test that enables clinics to respond more swiftly,ā states Marc Meier, managing director of Bosch Healthcare Solutions. Patients with compromised immune systems, such as those in intensive care, individuals with serious underlying conditions such as diabetes, or those who are immunosuppressed due to cancer or HIV, as well as patients about to undergo invasive surgery, face a heightened risk of active infection with C. auris. The mortality rate for C. auris infections ranges from 30 to 72 percent.
āCandida aurisĀ can be transmitted from person to person through contact and contaminated surfaces. When this fungus presents, rapid detection is therefore rapid detection is therefore paramount to enable implementation of effective control and prevention strategies,” says Dr. med. Alexander Maximillian Aldejohann,Ā deputy head of the WĆ¼rzburg Laboratory at the National Reference Center for Invasive Fungal Infections (NRZMyk.) Since July 2023, Germany has implemented a limited statutory reporting requirement under the Infection Protection Act. Aldejohann is in favor of extending this reporting obligation: āThe fungus has the capacity to rapidly develop resistance to many common antifungal agents coupled with the ability to survive for a relatively long time on surfaces. This high so-called tenacity also increases the risk of outbreaks that are difficult to contain.ā
Increasing spread of Candida auris
C. auris is spreading globally. In some states in the U.S, the annual incidence rate has been shown to increase by a factor of 2 to 3. The Robert Koch Institute (RKI) also drew attention to a rise in cases within Germany during the past year in the Epidemiological Bulletin at the at the beginning of May. The RKI points out that in specific areas screening could be beneficial. In the U.S, the annual case count has in the meantime reached the thousands. The Centres for Disease Control and Prevention (CDC) already consider the screening of patients, visitors, and staff for C. auris as a crucial strategy to curb its spread in healthcare settings. While the fungus is harmless for healthy individuals, it can it can lead to severe nosocomial infections, i.e. infections acquired in hospitals or other healthcare environments, in patients at high risk and, if the fungus enters the bloodstream, can trigger sepsis.
Easy handling, rapid detection The Vivalytic Analyser enables effortless testing directly at the point of care: The sample is placed into the test cartridge, which already contains all necessary reagents. The cartridge is then inserted into the Vivalytic Analyser for automated processing. Healthcare professionals require only minimal training to use the system, and the fully automated process significantly lowers the risk of infection. The Vivalytic Analyser thus facilitates rapid and precise diagnostics in PCR quality, bypassing the frequently lengthy process through a central laboratory. Bosch Healthcare Solutions is expecting CE certification for the Vivalytic C. auris test soon.
For More Information Please Contact:
Martin Conway, Phone: +44 (0) 28 9442 2413
E-mail: martin.conway@randox.co
Dementia Action Week 2024
Dementia Action Week 2024 (13th ā 20th May)
The term Dementia describes the different brain disorders that trigger a loss of brain function. These conditions are all usually progressive and eventually severe. Alzheimerās Disease is the most common type of dementia, affecting 62 per cent of all those diagnosed.
Dementia is a general term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life.Ā Common symptoms include memory loss, confusion, and speech problems. Early warning signs may also include finding it difficult to follow conversations, or programs on TV, forgetting names of friends, or everyday objects and feeling confused even in a familiar environment.
Mainly affecting older people, after the age of 65, the likelihood of developing dementia roughly doubles every five years ā however, for some dementia can develop earlier, presenting different issues for the person affected, their carer and their family. There is also a considerable economic cost associated with the disease estimated at Ā£23 billion a year, which is predicted to triple by 2040. This is more than the cost of cancer, heart disease, and stroke.
At Randox, we recognise the importance in diagnosing dementia early. Ā Through our Randox Ā Alzheimer’s Disease Array which can be used for Rapid Identification of Alzheimerās Disease Risk. Randoxās Alzheimerās Disease Risk Array can be used for the direct determination of ApoE4 status from plasma, eliminating the need for genetic testing, assisting in clinical research and personalised medicine strategies. At Randox, we believe the importance of measuring ApoE4 protein expression in plasma is the way forward to screen those individuals at increased risk of Alzheimer Disease, as new beta amyloid-targeting therapies for this condition are being expected.
Race Against Dementia have been the partner charity for the Randox Grand National Festival over the past two years, working alongside this charity which was founded by three-times Formula One World Champion, Sir Jackie Stewart, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
For further information about the Randox Alzheimerās Array please emailĀ info@randoxbiosciences.com
Serum Indices – Product Spotlight
Errors can occur at any point in the pre-analytical, analytical, or post-analytical stages of a diagnostic test. It is general practice for errors in the analytical stage to be identified through quality control procedures. However, pre-analytical errors are often treated with less importance than those in later stages of testing. Interference caused by haemolysis, icterus and lipemia (HIL) are common forms of pre-analytical error which affect assay methods, yielding erroneous results. The Randox Acusera Serum Indices (SI) control is designed to monitor an IVD instrument’s response in the detection of HIL interferences.
HIL interference is not novel and has been historically identified through a series of visual assessments. While haemolytic, icteric and lipemic interference causes a visual change in the sample, these methods are not quantitative and are subject to interpretation by laboratory professionals. Modern analysers have built-in capabilities for the automated detection of HIL interference which can quantitatively or semi-quantitatively measure haemolysis, icterus and lipemia, and provide and an index for each. This data can then be used to determine if a sample should be accepted for testing or rejected due to intrinsic interference.
The pre-analytical phase of laboratory testing includes collection, handling, transportation, storage, and preparation of samples. Even when the highest level of care is taken to ensure that all aspects of the pre-analytical phase are suitable and correct, errors can occur, exhibiting the need for clear and efficient quality control processes.
As part of our Acusera quality control range, Randox has developed the Serum Indices quality control to aid in the detection of the common pre-analytical error’s haemolysis, icterus and lipemia, collectively known as HIL. HIL interference can have disastrous effects on the quantification of many analytes, and it is therefore vital to determine levels of interference to improve laboratory efficiency and reduce the frequency of erroneous results.
The graph below shows the wavelengths at which each of these interferents may affect assays and the table below describes these forms of interference:
Classical determination of HIL interference took the form of a visual assessment. A sample was examined for tell-tale signs of one or more of these types of interference. However, these methods are subject to operator interpretation and lack harmonisation and uniformity across the industry. These signs are detailed in the table and illustrated in the graphic below:
Modern clinical chemistry analysers have onboard HIL detection capabilities which offer objective, semi-qualitative or qualitative analysis of these forms of interference in a more precise and consistent manner. Automation of HIL detection improves laboratory throughput along with test turnaround times and enhances the reportability of the results.
Errors at any stage of the analytical process will result in retesting of the sample. Errors in the pre-analytical phase can have repercussions such as increased cost of repeated sample collection and testing, poor test turnaround times, and more seriously, delayed or incorrect diagnosis causing an exacerbation in the condition of the patient. To add to the adverse outcomes on patients, repeated testing places additional stress on laboratory resources and staff which ultimately affects every aspect of a laboratory’s daily activities.
To correctly analyse HIL interference, absorbance readings at different strategically selected wavelengths supplement the calculation of the interference indices. C56-A recommends laboratories consider several parameters when selecting an HIL interference analysis method:
Before implementing results obtained from any method detecting HIL in patient samples, it is imperative to evaluate the specificity and sensitivity of the method at a minimum of two clinically relevant concentrations. This assessment should encompass the sensitivity of the icterus index to haemoglobin and lipids, the haemolysis index to bilirubin and lipids, and the lipemic index to haemoglobin and bilirubin.
In instances of HIL interference, laboratories bear the responsibility of managing the associated results and samples. It is crucial never to utilise an HIL index for the correction of patient results. Typically, if a sample is determined to be affected by one or more of these interferences, the laboratory should reject the result and appropriately dispose of the sample. Nonetheless, in certain scenarios, threshold values can be established. For instance, haemolysis may exert a lesser impact on samples with elevated analyte concentrations. In such cases, laboratories may opt for a distinct procedure in handling these results compared to those exhibiting haemolytic interference at lower analyte concentrations.
Acusera Serum Indices Control
The Randox Acusera Serum Indices (SI) control is designed to be used to monitor an IVD instrument’s response in the detection of haemolyzed, icteric and lipemic (HIL) samples. This control can be utilised in laboratory interference testing to assist in improving error detection of pre-analytical errors affecting clinical chemistry testing. This control provides a full range of clinically relevant testing levels, including a negative (-) and three positives (+, ++ & +++).
The Randox Control offers a comprehensive solution with 3 levels for each form of interference and a negative control, providing a wider coverage compared to alternatives in the market. Our product is conveniently supplied in a lyophilized format, ensuring an extended shelf-life and ease of storage. Customers appreciate the stability of our control, as it consistently meets the 14-day open stability claims, minimizing waste and optimizing laboratory efficiency.
Typical Values
RIQAS Serum Indices External Quality Assessment
The RIQAS Serum Indices EQA programme is designed for the pre-analytical assessment of Haemolytic, Icteric and Lipemic (HIL) interferences. Available in a bi-monthly format with the option to report either quantitative or semi-quantitative results for the HIL parameters, this programme also provides an assessment on how these interferences impact on up to 25 routine chemistry parameters. This provides invaluable information on whether a correct judgement is being made to report results.
• Lyophilised for enhanced stability
• Human based serum ensuring commutable sample matrix
• Bi-monthly reporting
• HIL parameters include the option of quantitative or semi-quantitative reporting
• Interpretation of chemistry parameter results
• Submit results and view reports online via RIQAS.net
How can Randox help?
It is crucial laboratories test for haemolysis, icterus and lipemia to ensure the accuracy of their test processes are maintained. ISO 15189:2022 promotes the identification and control of non-conformities in the pre-analytical process, therefore, using Randox Serum Indices control and RIQAS Serum Indices EQA will help laboratories fulfil the requirements of the new edition of this standard.
Randox Serum Indices control displays improved consolidation, stability, and commutability to ensure laboratories are equipped to accurately determine pre-analytical interferences. Our Serum Indices control can be used with most major chemistry analysers including Roche, Abbot, Beckman, Ortho, and Siemens. When used in conjunction with Acusera 24.7, this control offers laboratories the ability to compare their HIL results with their peer group and identify potential failures in their pre-analytical process.
Simply send us an email by clicking the link below and we will get in touch!
Medical Laboratory Professionals Week 2024
Medical Laboratory Professionals Week (MLPW) is recognised every year in the last full week of April. It’s an opportunity to increase the public understanding of, and appreciation for, the hard work of clinical laboratory staff around the world. It’s also an opportunity to inject a little fun into the laboratory. So, this year, we’ve created a Lab Professionals QC Bingo card. Have a go and see how many your laboratory can get!
How many boxes does your lab tick?
If you’re calling Bingo! you must be an Acusera 24.7 customer. If not, keep reading to find out how you can make daily life in your laboratory more straightforward.
What are Medical Laboratory Professionals?
Medicine wouldn’t be where it is today without the work of these laboratory professionals. They’re on the frontline. Around 70% of medical decisions are based on results provided by medical laboratory staff. That’s a lot of pressure on the labs to make sure their results are accurate. Clinical laboratory staff not only perform the tests used to guide diagnosis and disease prevention, but they also check all the tests they use through rigorous quality control (QC) procedures.
This involves testing samples of known values to prove that the test system and its components perform as they should and provide accurate results. To do this, laboratories require QC material. It’s important that what’s in a QC is as similar to what you’d find in a patient sample as possible. This is known as commutability. Good commutability helps limit cross-reactivity in the test and inaccurate results.
It’s also important to make sure the QC material has concentrations of analytes at similar values to those used to make diagnostic decisions. If you wanted to validate the length of the ruler on your desk, it wouldn’t be helpful to set it down on a 100m running track. Similarly, when laboratory professionals want to ensure a test is producing accurate results, they want to test the system at the critical values used to make medical decisions so that they can be confident the results at these values are accurate.
Once lab staff have confirmed the accuracy of their tests, they can begin testing patient samples. For most people, what happens to a sample after it’s taken is a bit of a mystery. MLPW is the perfect opportunity to unravel this a little:
After your sample is collected, it gets sent over to the lab. Even just moving it there needs careful handling to make sure it’s still good for testing when it arrives. Once it’s in the lab, the team checks the equipment to make sure it’s working right and giving accurate results. The QC procedure varies depending on what they’re testing for, but they always make sure their tests are legitimate. Once they’ve checked everything and carried out the tests, a pathologist looks at the results to figure out what’s going on. They use this information to help decide on the best treatment plan for you.
Even this watered-down explanation makes it sound like a lot of work, right? At Randox, we recognise the vital role and dedicated efforts of medical laboratory professionals, and the invaluable contributions they make to society, and we hope that now, you do too.
Acusera 24.7
Bingo! That’s exactly how our customers feel when they realise how much time Acusera 24.7 can save them. Our innovative and intuitive QC data software is cloud-based, allowing you to log in from anywhere in the world to review your QC data.
Along with a wide range of interactive charts, including Levey-Jennings charts, Acusera 24.7 determines measurement uncertainty and sigma metrics for you, saving you the time and stress of manually calculating these tricky statistical analyses. And that’s just the beginning. Acusera 24.7 can link to LIMS for automated data entry, meaning lab staff don’t have to manual type long datasets, unless they want to of course; we also provide both semi-automated data upload and manual data entry options.
Access to a range of reports has never been easier. Acusera 24.7 is particularly useful when gaining or renewing your accreditation, and live peer group QC data, to give additional confidence in the accuracy of your results.
But this article is supposed to be about laboratory professionals, so we won’t bang on about it anymore. We just want everyone to know about Acusera 24.7 so they can get that daily bingo! feeling for themselves. If you want to learn more about our reports, charts, advanced statistical analysis, Acusera 24.7 more generally, or how Acusera 24.7 can help you achieve your accreditation, you can follow the links to the relevant blog post.
Last year, we interviewed two of our laboratory staff, Dean and Meadhbh, to find out what a normal day looked like for them. To find out what a day in the life of a laboratory professional is like, take a look at the interviews here
If you’d like to get in touch with us to discuss the advantages of Acusera 24.7, or you’ve made up your mind and want to get in on the action, reach out to us at marketing@randox.com. We’re always happy to brag about how great Acusera 24.7 is, and how we make life simpler for more and more laboratories every day.
Growth through medical technology: Randox and Bosch invest heavily in the Vivalytic analysis platform
-
New partnership for Vivalytic analysis platform: Bosch and Randox
-
Laboratories Ltd. to invest 150 million euros in research, development, and
-
distribution
-
Strategic growth field: point-of-care molecular diagnostics expected to
-
become a future market worth billions
-
Growth with fully automated laboratory diagnostics: the two companies aim to
-
achieve sales in the nine-figure range by 2030.
-
Smartphone-sized laboratory: sepsis IVD grade test based on cutting-edge
-
BioMEMS technology is a joint development objective.
With many diseases, every minute counts, and determining whether a patient is presenting the symptoms of a simple cold, the flu, or something as severe as life-threatening meningitis is usually only possible after time-consuming and expensive
laboratory diagnostics. With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care ā and aims to use molecular diagnostics to become a leading provider in the
market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company. The two companies will invest around 150 million euros in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare. One goal is the development ofĀ a sepsis IVD1 grade test that will be the first to feature highly innovative and novel BioMEMS technology.
Bosch has defined medical technology as a strategic growth field. Point-of-care molecular diagnostics is expected to become a future market worth billions. And with its Vivalytic analysis platform, Bosch aims to achieve a leading position in this market. āWith cutting-edge technology from our own labs and our own production lines, we want to grow long-term together with partners in the field of precision diagnostics,ā says Stefan Hartung, chairman of the Bosch board of management. āHere, our medical technology can draw considerable benefit from our diversification, from our expertise, from the groundwork we have done in automation, miniaturization, molecular diagnostics, and from our experience in microchip development and manufacturing,ā Hartung adds. āWe are investing long-term in an exciting high-tech growth field and continuously developing it together with partners. With technology āInvented for lifeā, we can relieve the burden on medical professionals and help make the diagnose and treatment of disease fasterā.
Shared growth: decentralized diagnostics at the point of care
Bosch Healthcare Solutions and Randox are now joining forces in an attempt to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years. With Vivalytic, the two companies aim to achieve sales in the medium nine-figure range by 2030. āGlobally, healthcare is moving toward decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,ā says Marc Meier, managing director of Bosch Healthcare
Solutions GmbH. āWith our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular diagnostics PCR tests provide clarity directly at the site of sample collection,
shorten waiting times, and take the strain off the healthcare system,ā Meier adds. The two partners are a good fit: Bosch can contribute its technology and manufacturing expertise across the fields of molecular diagnostics, microchip
development and manufacturing, and miniaturization. The universal Vivalytic platform for molecular diagnostics was developed in over ten years by Bosch researchers and brought to market maturity by Bosch Healthcare Solutions. Randox has 40 years of experience in the design and development of highly sensitive IVD tests performed on a variety of technologies, including microfluidic platforms. In combination with the companyās extensive market knowledge and global sales and distribution network, this adds up to considerable opportunities for growth. āRandox has always been committed to improving health worldwide and sees the need to invest in research and development initiatives that will support clinical decision making across a variety of disease areas. Diagnostics has always been an indispensable component of healthcare, and the alignment of both science and technology makes for the perfect fit in an area for high potential impact, especially in pressure-driven environments,ā says Dr. Peter Fitzgerald, Managing Director of Randox Laboratories Ltd. Bosch Healthcare Solutions and Randox already collaborated during the Covid-19 pandemic. In spring 2020, Bosch launched one of the worldās first fully automated PCR tests for the SARS-CoV-2 coronavirus. Together with Randox, the rapid test for use in doctorās offices, nursing homes, testing stations, and hospitals was made ready for the Vivalytic analysis device within the space of just a few weeks.
Development goal: sepsis test based on BioMEMS technology
One focus of the development partnership with Randox is the implementation of a highly sensitive multiplex2test for sepsis on the Vivalytic analysis platform.Sepsis, also known as āblood poisoning,ā is a potentially life-threatening complication3 that can occur in conjunction with various infectious diseases. A medical emergency that can lead to multiple organ failure, it requires immediate medical treatment. The planned IVD grade sepsis test is to be based for the first time on the highly innovative and novel BioMEMS technology developed by teams from Bosch corporate research in Renningen and Bosch Healthcare Solutions in Waiblingen. āWe have set ourselves the ambitious goal
of adding the functions of a high-performance silicon chip based on microsystems technology to our test cartridges for the Vivalytic platform. In doing so, we will combine Boschās unique expertise in the areas of MEMS chips, molecular diagnostics, and microfluidics,ā Marc Meier says. āClinical outcomes in sepsis depend on timely diagnosis and appropriate early therapeutic intervention. Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using the highly multiplexing BioMEMS technology. Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition,ā says Dr. Peter Fitzgerald.
Smaller and faster: from microfluidics to nanofluidics ā thanks to BioMEMS
The powerful BioMEMS chip adds a further innovative analysis method to the Vivalytic test cartridge, enabling it to test simultaneously and significantly faster for a large number of different pathogens. It is called BioMEMS because it combines microelectromechanical systems (MEMS) with microfluidics for applications in the field of medical technology. In microfluidics, very small amounts of fluid in the microliter range are moved in a very small space. Miniaturization allows qualitative biochemical polymerase chain reactions (PCR) to run in parallel in real-time on a single BioMEMS chip. āCompared to previous PCR reactions, the volumes of liquids are reduced by a factor of 1,000 to the nanoliter range. The analysis of liquids is left to a small microchip,ā Marc Meier explains. With the new BioMEMS technology, fully automatic testing up to 250 genetic characteristics4 (e.g. pathogens) in one cartridge is possible in less
than 15 minutes. The test cartridge is a highly complex laboratory the size of a smartphone, so to speak. Another future advantage of BioMEMS will be simpler and faster adaptation of new tests or existing tests on the chip itself. For example, existing tests can easily be expanded to include additional features. āThe BioMEMS technology paves the way for us to move into nanofluidics, where each pathogen will be examined in a reaction vessel the thickness of a hair,ā Meier says. To achieve this, Bosch wants to create more capacity on a MEMS chip and expand it what are known as ānanocavitiesā. Thanks to t
hese very small cavities, even more biochemical processes will be able to run in parallel on a
chip. With increasing miniaturization, the technology has potential to be used in oncology as well over the long term. The BioMEMS chips are to be manufactured at the Bosch semiconductor plant in Reutlingen, with bio-integration and cartridge
assembly to be carried out at Bosch Healthcare Solutions in Waiblingen.
Vivalytic platform: easy application at the point of sample collection
The advantages of carrying out PCR tests on the Bosch Vivalytic platform lie not only in speedy a
nalysis, but also in the ease of use: Once the sample has been taken, it is placed in the test cartridge. The cartridge, which contains all the necessary reagents for the respective test, is then inserted into the Vivalytic analyser for automated evaluation. Medical staff require only brief training on how to operate it. This enables fast and targeted diagnostics directly at the point of sample collection ā either at the doctorās office or in the hospital ā without the often long and time-consuming detour via a central laboratory. Bosch Healthcare Solutions already distributes various tests for diseases of the upper and lower respiratory tract, such as SARS-CoV-2 ā also a pooling variant and as a saliva test ā or a test to differentiate between SARS-CoV-2, RSV virus and influenza. There are also tests for pathogens that cause sexually transmitted infections (STI) and MRSA / SA (āhospital germā). Starting in summer, it is planned to expand the portfolio with tests for whooping cough (Bordetella holmesii, Bordetella parapertus
sis, and Bordetella bronchiseptica), urinary tract infections (UTI), bacterial meningitis, the two most common sexually transmitted diseases (Chlamydia trachomatis; CT and Neisseria gonorrhoeae; (NG), fungal infections (Candida auris), and three tests for diarrheal diseases
(norovirus, Clostridioides difficile, HSP)
Contact persons for press inquiries:
Robert Bosch GmbH
Dƶrthe Warnk, Phone: +49 711 811-55508
E-mail: doerthe.warnk@bosch.com
Randox Laboratories Ltd.
Martin Conway, Phone: +44 (0) 28 9442 2413
E-mail: martin.conway@randox.com
Randox announce ‘Race Against Dementia’ as partner charity for Randox Grand National Festival 2024.
Race Against Dementia is announced as partner charity for Randox Grand National Festival 2024. The charity was founded by three-times Formula One World Champion, Sir Jackie Stewart, OBE, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
Race Against Dementia is announced as partner charity for Randox Grand National Festival 2024. This will be their second consecutive year as partner charity. Founded by three-times Formula One World Champion, Sir Jackie Stewart OBE, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
Race Against Dementia’s vision is to one day win the race against dementia by accelerating global research towards a breakthrough cure. Together we can beat dementia – faster. Currently more than 55 million people are affected by dementia worldwide. Sadly, unless something changes, 1 in 3 people born today will die with dementia.
Dementia affects different parts of the brain; some people with dementia may have trouble remembering things, while others may have trouble with language or performing tasks they used to do easily. There are many types of dementia. Each one can affect people differently, causing problems with memory, thinking and behaviour. There is unfortunately, no cure currently for this progressive disease.
As pioneers of prevention and 4-year principal partner of the Randox Grand National, Randox is proud to spread awareness of the power of preventative testing which can identify fences to clear in your health early and make you a front runner for a healthier future. As a global diagnostics company, with over 40 years of experience and a focus on preventative healthcare, Randox and Race Against Dementia are natural partners.
Throughout the three-day festival at Aintree, the charity partner will be supported to highlight the impact of the disease and to raise funds for much needed research into its prevention and cure. On Ladies Day (Friday 12th April), Randox’s sponsored race over the Grand National Fences will be titled ‘The Randox Supports Race Against Dementia Topham Chase’, with opportunities to reach out to both the racing public, and through the festival’s media coverage, to the nation.
In the pursuit of a cure for dementia, improved testing and diagnosis will both enhance patient management and greatly accelerate the race for treatment. In the last 12 months, Randox have processed over 5 million tests from health-conscious clients across the UK & Ireland, through our accessible and comprehensive in-clinic and at-home testing services.
Randox provides access to unrivalled insights that allow you to take control of your health, empowering you to makeĀ simple lifestyle changes that could help protect future illness. Also offering specific tests across key health areas including sexual health, hormonal health, digestive, and a range of genetic and other health testing both at-home and in-clinic, at one of our health clinics located throughout the UK and now in selected John Lewis stores – providing easy access for millions of people to a new range of preventative health packages designed to help clients take control of their health.
Sir Jackie Stewart OBE, Founder of Race Against Dementia: “The Randox Grand National is truly a highlight in the sporting calendar. We, at Race Against Dementia are very grateful to Randox Laboratories for supporting us once again this year. Someone is diagnoses with dementia every three seconds and together, through raising funds and awareness, we can accelerate progress towards finding both a prevention and a cure for dementia.
Dr. Peter FitzGerald, Managing Director of Randox: “We are once again proud to partner with Race Against Dementia as our nominated charity for the Randox Grand National Festival 2024 – Race Against Dementia is a cause very close to our hearts!
“As a global diagnostics company, with over 40 years of experience and a focus on preventative healthcare, Randox and Race Against Dementia are natural partners.”
For more information please visit: raceagainstdementia.com/what-is-dementia/Ā
Kate Middleton’s diagnosis reminds us that early detection is key
Kate Middleton’s recent cancer diagnosis has highlighted the importance of early detection to us all. Detecting potential health issues early means individuals can work with healthcare professionals to implement treatment plans, lifestyle changes, or preventative measures. These could mitigate, or even prevent the progression of certain diseases.
An article published by the Daily Mail, which focuses on early cancer detection MOT’s, emphasises the importance of preventative testing and treatment throughout. Charlotte Griffiths, who underwent our Everywoman Plus Tumour-Associated Markers test, stated that it is vital to keep a watchful eye for any unexpected bodily changes, such as unexplained bumps or weight loss, which may indicate a presence of cancer.
At Randox Health, we test for a range of different tumour markers, as well as genetic testing, to deliver information on cancer risk to an individual. This aims to empower people to be proactive towards improving their health and makes them aware of any potential future health risks they may have.
It is estimated that 30-50% of all cancer cases are avoidable, and in many cases, early detection is key and can save lives. Cancer that’s diagnosed at an early stage, when it isn’t too large and hasn’t spread, is more likely to be treated successfully.
Spotting cancer at an early stage can save lives, however many people do not have access to the information or services to facilitate this detection. Over 8 million people in the UK are currently awaiting diagnostic testing. At Randox Health, with over 40 years’ experience in working towards improving healthcare worldwide, we have a focus on preventative healthcare; aiming to achieve better health outcomes whilst reducing the burden on clinical services.
At Randox Health we offer genetic risk tests for inherited cancers, including Breast and Ovarian Cancer, Bowel Cancer, and others. In addition, we offer a range of full-body health tests that include common tumour-associated markers.
The results from your tests allow you to get a more accurate representation of your current health status, as well as giving you the ability to make lifestyle changes to potentially prevent future health risks.
Discover our health checks at randoxhealth.com
